<H1>Chapter DOI: 10.1208/aapsj070487<br/>Cited-By Count: 4</H1><table border="1" width="30%"><tr><td>Total References</td><td>35</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>35</td></tr><tr><td>BibStructured Count</td><td width="10%">35</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>20</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>1</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>George JN, Woolf SH, Raskob GE, et al. Idiopathic throm bocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.<Emphasis Type="Italic">Blood.</Emphasis> 1996;88:3&#8211;40.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Imbach P, Barandun S, d&#8217;Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic throm bocytopenic purpura in childhood.<Emphasis Type="Italic">Lancet.</Emphasis> 1981;1:1228&#8211;1231.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(81)92400-4>10.1016/S0140-6736(81)92400-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Bussel JB, Hilgartner MW. Intravenous immunoglobulin therapy of idiopathic thrombocytopenic purpura in childhood and adolescence.<Emphasis Type="Italic">Hematol Oncol Clin North Am.</Emphasis> 1987;1:465&#8211;482.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Adams JR, Nathan DP, Bennett CL. Pharmacoeconomics of therapy for ITP: steroids, i.v.Ig, anti-D, and splenectomy.<Emphasis Type="Italic">Blood Rev.</Emphasis> 2002;16:65&#8211;67.</td><td><a href=http://dx.doi.org/10.1054/blre.2001.0186>10.1054/blre.2001.0186</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Gomperts ED. Gammagard and reported hepatitis C virus episodes.<Emphasis Type="Italic">Clin Ther.</Emphasis> 1996;18:3&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0149-2918(96)80192-5>10.1016/S0149-2918(96)80192-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Milgrom H. Shortage of intravenous immunoglobulin.<Emphasis Type="Italic">Ann Allergy Asthma Immunol.</Emphasis> 1998;81:97&#8211;100.</td><td><a href=http://dx.doi.org/10.1016/S1081-1206(10)62792-5>10.1016/S1081-1206(10)62792-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-sose intravenous gamma globulin.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 1982;306:1254&#8211;1258.</td><td><a href=http://dx.doi.org/10.1056/NEJM198205273062102>10.1056/NEJM198205273062102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.<Emphasis Type="Italic">Blood.</Emphasis> 2002;100:2087&#8211;2093.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by antiidiotypic antibodies in intravenous gammaglobulin.<Emphasis Type="Italic">Blood.</Emphasis> 1989;74:2414&#8211;2417.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia.<Emphasis Type="Italic">Lancet.</Emphasis> 1983;2:193&#8211;195.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(83)90175-7>10.1016/S0140-6736(83)90175-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases.<Emphasis Type="Italic">J Allergy Clin Immunol.</Emphasis> 1997;100:151&#8211;157.</td><td><a href=http://dx.doi.org/10.1016/S0091-6749(97)70217-3>10.1016/S0091-6749(97)70217-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Tovo PA, Miniero R, Fiandino G, Saracco P, Messina M. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP.<Emphasis Type="Italic">J Pediatr.</Emphasis> 1984;105:676&#8211;677.</td><td><a href=http://dx.doi.org/10.1016/S0022-3476(84)80455-2>10.1016/S0022-3476(84)80455-2</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, Year, ArticleTitle, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.<Emphasis Type="Italic">Lancet.</Emphasis> 1993;342:945&#8211;949.</td><td><a href=http://dx.doi.org/10.1016/0140-6736(93)92000-J>10.1016/0140-6736(93)92000-J</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Lobo ED, Soda DM, Balthasar JP. Application of pharmacokineticpharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 2003;92:1665&#8211;1676.</td><td><a href=http://dx.doi.org/10.1002/jps.10432>10.1002/jps.10432</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2001;298:165&#8211;171.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Tayab ZR, Balthasar JP. Development and validation of enzymelinked immunosorbent assay for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma.<Emphasis Type="Italic">J Immunoassay Immunochem.</Emphasis> 2004;25:335&#8211;344.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.<Emphasis Type="Italic">J Lab Clin Med.</Emphasis> 1951;38:1&#8211;10.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura: physiologic, serologic and isotopic studies.<Emphasis Type="Italic">Ann N Y Acad Sci.</Emphasis> 1965;124:499&#8211;542.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1965.tb18984.x>10.1111/j.1749-6632.1965.tb18984.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia.<Emphasis Type="Italic">Blood.</Emphasis> 1982;59:23&#8211;26.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Woods VL Jr, Kurata Y, Montgomery RR, et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura.<Emphasis Type="Italic">Blood.</Emphasis> 1984;64:156&#8211;160.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Fujisawa K, Tani P, McMillan R. Platelet-associated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens.<Emphasis Type="Italic">Blood</Emphasis>. 1993;81:1284&#8211;1289.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Hou M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies.<Emphasis Type="Italic">Br J Haematol.</Emphasis> 1997;98:64&#8211;67.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2141.1997.1883006.x>10.1046/j.1365-2141.1997.1883006.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Snyder HW, Jr, Cochran SK Jr, Balint JP Jr, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune throm bocytopenic purpura.<Emphasis Type="Italic">Blood.</Emphasis> 1992;79:2237&#8211;2245.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Guthrie TH Jr, Oral A. Immune thrombocytopenia purpura: a pilot study of staphylococcal protein A immunomodulation in refractory patients.<Emphasis Type="Italic">Semin Hamatol.</Emphasis> 1989;26:3&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism.<Emphasis Type="Italic">Nature.</Emphasis> 1964;203:1352&#8211;1354.</td><td><a href=http://dx.doi.org/10.1038/2031352a0>10.1038/2031352a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat.<Emphasis Type="Italic">J Clin Invest.</Emphasis> 1972;51:2916&#8211;2927.</td><td><a href=http://dx.doi.org/10.1172/JCI107116>10.1172/JCI107116</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens.<Emphasis Type="Italic">Nature.</Emphasis> 1989;337:184&#8211;187.</td><td><a href=http://dx.doi.org/10.1038/337184a0>10.1038/337184a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.<Emphasis Type="Italic">Immunology</Emphasis>. 1996;89:573&#8211;578.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2567.1996.d01-775.x>10.1046/j.1365-2567.1996.d01-775.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulindeficient mice.<Emphasis Type="Italic">Eur J Immunol.</Emphasis> 1996;26:690&#8211;696.</td><td><a href=http://dx.doi.org/10.1002/eji.1830260327>10.1002/eji.1830260327</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.<Emphasis Type="Italic">Proc Natl Acad Sci USA.</Emphasis> 1996;93:5512&#8211;5516.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.11.5512>10.1073/pnas.93.11.5512</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.<Emphasis Type="Italic">Thromb Haemost.</Emphasis> 2002;88:898&#8211;899.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 2003;92:1206&#8211;1215.</td><td><a href=http://dx.doi.org/10.1002/jps.10364>10.1002/jps.10364</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Bussel JB. Another interaction of the FcR system with IVIG.<Emphasis Type="Italic">Thromb Haemost.</Emphasis> 2002;88:890&#8211;891.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Vaughn DE, Bjorkman PJ. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization.<Emphasis Type="Italic">Biochemistry.</Emphasis> 1997;36:9374&#8211;9380.</td><td><a href=http://dx.doi.org/10.1021/bi970841r>10.1021/bi970841r</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 2004;93:2645&#8211;2668.</td><td><a href=http://dx.doi.org/10.1002/jps.20178>10.1002/jps.20178</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>